|
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine Clinical research trials and A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine. A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine  A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine
For Condition: HIV Infections
Status: Terminated
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: The purpose of this trial is to determine the safety and immunogenicity of an HIV-1 pseudovirion vaccine given at one antigen dose alone and in combination with each of two different adjuvants using two immunization schedules. The pseudovirions are virus-like particles generated by in vitro production of HIV-1 viral proteins which are capable of assembly into particles. The presence of gag gene products in addition to envelope glycoprotein should assist in humoral and cellular immunologic responses to internal HIV-1 viral proteins. The pseudovirion vaccine has been tested in preclinical trials in mice, guinea pigs, rabbits, and nonhuman primates with good safety and immunogenicity profile.
Details: The pseudovirions are virus-like particles generated by in vitro production of HIV-1 viral proteins which are capable of assembly into particles. The presence of gag gene products in addition to envelope glycoprotein should assist in humoral and cellular immunologic responses to internal HIV-1 viral proteins. The pseudovirion vaccine has been tested in preclinical trials in mice, guinea pigs, rabbits, and nonhuman primates with good safety and immunogenicity profile. A total of 78 volunteers will be recruited and randomly assigned to receive pseudovirion vaccine and/or the placebo/adjuvant. All volunteers will receive injections intramuscularly at 0, 1, 3, 6, and 12 months. Group I (30 volunteers): pseudovirion vaccine w/adjuvant or w/o adjuvant. Group II (30 volunteers): pseudovirion vaccine w/adjuvant or w/o adjuvant. Group III (18 volunteers): adjuvant (QS21 or alum) or saline placebo. NOTE: Group I will receive appropriate adjuvant or saline placebo at Month 3 without pseudovirion vaccine.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: 18 Years/60 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - Negative ELISA for HIV-1 antibody within 8 weeks of initial immunization. - CD4 count >= 400 cells/mm3. - Negative Hepatitis B surface antigen. - Normal history and physical examination. Exclusion Criteria Co-existing Condition: Patients with the following conditions and symptoms are excluded: - Medical or psychiatric condition or occupational responsibilities preclude compliance with the protocol. - Present psychosis. - Active syphilis (eligible if serology documented to be a false positive or due to remote, i.e., > 6 months treated infection). - Active tuberculosis (eligible if positive purified protein derivative test and normal chest x-ray showing no evidence of TB and not requiring isoniazid therapy). - Hepatitis B antigenemia. Concurrent Medication: Excluded: Immunosuppressive medications. Patients with the following prior conditions are excluded: - History of immunodeficiency, chronic illness, malignancy, or autoimmune disease. - History of cancer unless there has been surgical excision followed by sufficient observation period to give a reasonable assurance of cure. - History of suicide attempts, recent suicidal ideation or who have past psychosis. - History of anaphylaxis or other serious adverse reactions to vaccines. - History of serious allergic reaction to any substance, requiring hospitalization or emergent medical care (e.g. Stevens-Johnson syndrome, bronchospasm, or hypotension). Prior Medication: Excluded: - Prior receipt of HIV-1 vaccines or placebo recipient in a previous HIV vaccine trial. - Use of experimental agents within 30 days prior to study. - Live attenuated vaccines within 60 days of study. - Medically indicated subunit or killed vaccines (e.g., influenza, pneumococcal) within 2 weeks prior to study. Prior Treatment: Excluded: Receipt of blood products or immunoglobulin in the past 6 months. Risk Behavior: Excluded: Volunteers having identifiable higher risk behavior for HIV infection as determined by screening questions designed to identify risk factors for HIV infection, specifically: - History of injection drug use within the last 12 months prior to enrollment. - Higher or intermediate risk sexual behavior as defined by the AVEG ( i.e., meeting the criteria for AVEG Risk Group C or D). Volunteers risk behavior for HIV infection will be determined upon information obtained from a questionnaire and from the AIDS Vaccine Evaluation Group (AVEG) risk behavior guidelines. NOTE: - Only those volunteers meeting the criteria for AVEG Risk Groups A and B will be enrolled in this study.
Total Enrollment: 78
Location and Contact Information:
Overall Study Official:
GorseG, Study Chair,
Additional Information:
Study ID Numbers: AVEG 025;
Study Start Date:
Record last reviewed: October 1995
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000835
Other Hiv Infections Studies:
1. Phase III PEG-Intron in HIV-infected patients
2. Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily
3. A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers
4. A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects
5. A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons
Related Studies:
Other HIV Infections Clinical Trials
Other Clinical Trials
Other Clinical Trials
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine
|
|
|
|
|
|
|
|
